logo-loader
Lexaria Bioscience Corp

Lexaria Bioscience renews CEO Chris Bunka and President John Docherty's contracts

The new contracts last for three years and will allow the company to make sure its senior team stays in place in the near-term

cannabis plant
Lexaria has also reached agreements to cancel 1.14 million stock options with exercise prices ranging from US$0.10 to US$2.06

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), the cannabis company, announced Tuesday that it has successfully renewed the management contracts for both its CEO Chris Bunka and its President John Docherty.

The new contracts last for three years and will allow the Kelowna, British Columbia-based company to make sure its senior team stays in place at a time when its business is growing considerably.

READ: Lexaria Bioscience announces optimistic new trial results for its hemp oil capsule TurboCBD

In other news, Lexaria also said it has reached agreements to cancel 1.14 million stock options with exercise prices ranging from US$0.10 to US$2.06.

The backbone of Lexaria’s business is a technology called Dehydratech. Essentially, it allows cannabidiol (CBD) and other oils to be dehydrated into an odorless, tasteless powder and mixed with xanthan gum, corn flour and other base ingredients which can then be added to foods, drinks and creams.

Lexaria has multiple patents pending in over 40 countries and already has patents in the US and in Australia for Dehydratech.

Lexaria shares slipped C$0.09 to hit C$1.43 on Tuesday.

-- This story is updated to reflect latest share price movement -- 

Contact Ellen Kelleher at [email protected]

 

 

Quick facts: Lexaria Bioscience Corp

Price: $0.87

Market: CSE
Market Cap: $68.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp named herein, including the promotion by the Company of Lexaria Bioscience Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bioscience ChrgD up about CBD product launch in the U.S.

Lexaria BioScience (CSE: LXX-OTCQX-LXRP) CEO Chris Bunka joined Steve Darling from Proactive Canada to discuss the company launching a new product featuring hemp oil in a powdered format.  Bunka talks about ChrgD and why this product can demonstrate Lexaria's ability to deliver CBD into...

3 weeks, 4 days ago

2 min read